Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. on April 12, 2018. The report addresses a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a regulatory milestone and does not contain financial statements.
Material Changes
On April 12, 2018, the Korean Ministry of Food and Drug Safety approved the addition of a sixth cohort to the Company's Phase 1/2 clinical trial of CB 2679d/ISU304. This trial focuses on individuals with hemophilia B.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the regulatory approval. No specific financial guidance, management outlook, or discussion of risks and contingencies is included in the text of this 8-K.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the sixth cohort.
- Confirm the current status of the Phase 1/2 trial for CB 2679d/ISU304 in hemophilia B.
- Review subsequent filings for any financial impact or updated clinical trial timelines resulting from this approval.